Non-Prescribed Use of Opioid Agonist Medications and Associations with Non-Fatal Overdoses: A Repeated Cross-Sectional Study across a Decade of Reduced Monitoring
European Addiction Research · 2025
DOI: 10.1159/000547909 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift European Addiction Research, 2025. Verfasst von Anne Line Bretteville-Jensen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Alcohol, Tobacco, and Drugs, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Drug Overdose, Analgesics, Opioid, Buprenorphine, Methadone. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Non-prescribed use of opioid agonist treatment (OAT) medications is a public health concern. This study analyzes the prevalence of non-prescribed use and non-fatal overdoses in Norway in 2013 and 2023, a period marked by an increasingly flexible OAT regimen, and examines associations between non-prescribed use and non-fatal overdoses.
Methods
Cross-sectional surveys with two convenience samples (n1 = 611 in 2013, n2 = 523 in 2023) of street-recruited individuals, who reported recent use of opioids and/or stimulants but were not currently enrolled in OAT, were employed. The primary outcomes were self-reported non-prescribed use of methadone and buprenorphine and non-fatal overdoses in the past month and past year. Covariates included demographics and substance use characteristics.
Results
Non-prescribed use of OAT medications significantly declined from 39.4% in 2013 to 28.1% in 2023 (p < 0.001), as did frequency of use (p < 0.01). There was no change in non-fatal overdoses in the past month (8.2% in both years), though past-year non-fatal overdoses decreased (23.6% in 2013 vs. 15.9% in 2023, p = 0.001). Multinomial regression analyses showed no significant association between non-prescribed OAT use and increased risk of non-fatal overdoses. Instead, factors such as injecting drug use, frequent heroin use, stimulant use, younger age, and female sex were associated with non-fatal overdose risk.
Conclusion
Even with an increasingly flexible OAT regimen, non-prescribed use declined among street-recruited participants, and no corresponding increase in non-fatal overdoses was observed. These findings challenge the assumption that reduced monitoring in OAT is linked with higher rates of non-prescribed use and adverse outcomes, such as non-fatal overdoses, among individuals not in OAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Alcohol, Tobacco, and Drugs, Norwegian Institute of Public Health, Oslo, Norway.
- Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Zitieren
APA
Bretteville-Jensen, A. L., & Nesse, L. (2025). Non-Prescribed Use of Opioid Agonist Medications and Associations with Non-Fatal Overdoses: A Repeated Cross-Sectional Study across a Decade of Reduced Monitoring. European Addiction Research. https://doi.org/10.1159/000547909
Vancouver
Bretteville-Jensen AL, Nesse L. Non-Prescribed Use of Opioid Agonist Medications and Associations with Non-Fatal Overdoses: A Repeated Cross-Sectional Study across a Decade of Reduced Monitoring. European Addiction Research. 2025. doi:10.1159/000547909
BibTeX
@article{BrettevilleJensen2025,
author = {Bretteville-Jensen, Anne Line and Nesse, Linda},
title = {Non-Prescribed Use of Opioid Agonist Medications and Associations with Non-Fatal Overdoses: A Repeated Cross-Sectional Study across a Decade of Reduced Monitoring},
journal = {European Addiction Research},
year = {2025},
doi = {10.1159/000547909}
}
EUVIMED